Eli Stock Based Compensation from 2010 to 2024

LLY Stock

USD 749.92 3.49 0.46%

Eli Lilly Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation will likely drop to about 334.2 M in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

1995-09-30

Previous Quarter

211.1 M

Current Value

133.2 M

Quarterly Volatility

372.7 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Eli Lilly financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eli Lilly's main balance sheet or income statement drivers, such as Depreciation And Amortization of 941.5 M, Interest Expense of 510.2 M or Total Revenue of 35.8 B, as well as many indicators such as Price To Sales Ratio of 16.21, Dividend Yield of 0.0073 or PTB Ratio of 51.34. Eli financial statements analysis is a perfect complement when working with Eli Lilly Valuation or Volatility modules.

Check out the analysis of Eli Lilly Correlation against competitors.

Latest Eli Lilly's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Eli Lilly and over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Eli Lilly's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eli Lilly's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Eli Stock Based Compensation Regression Statistics

	Arithmetic Mean	199,952,000
	Coefficient Of Variation	166.99
	Mean Deviation	177,528,000
	Median	279,500,000
	Standard Deviation	333,898,086
	Sample Variance	111487.9T
	Range	1.6B
	R-Value	0.68
	Mean Square Error	63998T
	R-Squared	0.47
	Significance	0
	Slope	51,020,214
	Total Sum of Squares	1560831T

Eli Stock Based Compensation History

	2024	334.2 M
	2023	628.5 M
	2022	371.1 M
	2021	342.8 M
	2020	308.1 M
	2019	312.4 M
	2018	279.5 M

Other Fundumenentals of Eli Lilly

Stock Based Compensation To Revenue

Eli Lilly Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Debt	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Good Will	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.11	0.83	0.08	0.94	0.95	0.97	0.74	0.72	0.96	-0.27	-0.68	-0.68	0.85	0.59	0.87	0.61	0.8	-0.49	0.63	0.78	-0.07	0.74	-0.34	0.42	-0.59
Total Stockholder Equity	0.11		-0.34	0.97	-0.1	-0.19	0.09	-0.18	0.02	0.03	0.75	0.56	0.56	-0.39	-0.1	0.26	-0.1	-0.12	0.72	-0.54	-0.35	0.74	-0.12	0.27	0.3	0.18
Net Debt	0.83	-0.34		-0.4	0.93	0.93	0.77	0.83	0.73	0.91	-0.58	-0.92	-0.92	0.94	0.54	0.65	0.67	0.93	-0.73	0.8	0.86	-0.41	0.8	-0.66	0.41	-0.84
Retained Earnings	0.08	0.97	-0.4		-0.18	-0.22	0.06	-0.21	-0.05	-0.03	0.81	0.62	0.62	-0.42	-0.03	0.21	-0.08	-0.22	0.71	-0.57	-0.41	0.8	-0.17	0.38	0.16	0.29
Net Receivables	0.94	-0.1	0.93	-0.18		0.96	0.92	0.78	0.74	0.97	-0.48	-0.83	-0.83	0.92	0.51	0.79	0.59	0.9	-0.59	0.74	0.85	-0.27	0.8	-0.51	0.51	-0.74
Total Liab	0.95	-0.19	0.93	-0.22	0.96		0.93	0.8	0.69	0.94	-0.49	-0.84	-0.84	0.96	0.62	0.79	0.66	0.82	-0.71	0.8	0.89	-0.29	0.76	-0.43	0.33	-0.64
Total Current Assets	0.97	0.09	0.77	0.06	0.92	0.93		0.61	0.74	0.91	-0.27	-0.62	-0.62	0.82	0.53	0.84	0.53	0.72	-0.45	0.61	0.76	-0.07	0.78	-0.18	0.44	-0.5
Intangible Assets	0.74	-0.18	0.83	-0.21	0.78	0.8	0.61		0.37	0.79	-0.4	-0.77	-0.77	0.83	0.52	0.64	0.79	0.79	-0.71	0.75	0.72	-0.17	0.45	-0.71	0.19	-0.68
Short Term Debt	0.72	0.02	0.73	-0.05	0.74	0.69	0.74	0.37		0.77	-0.18	-0.51	-0.51	0.56	0.26	0.51	0.37	0.75	-0.19	0.31	0.5	-0.06	0.95	-0.28	0.65	-0.73
Accounts Payable	0.96	0.03	0.91	-0.03	0.97	0.94	0.91	0.79	0.77		-0.34	-0.75	-0.75	0.87	0.54	0.81	0.64	0.91	-0.5	0.64	0.78	-0.14	0.81	-0.52	0.53	-0.77
Short Term Investments	-0.27	0.75	-0.58	0.81	-0.48	-0.49	-0.27	-0.4	-0.18	-0.34		0.78	0.78	-0.66	-0.24	-0.16	-0.2	-0.4	0.75	-0.73	-0.67	0.88	-0.26	0.42	-0.03	0.35
Capital Stock	-0.68	0.56	-0.92	0.62	-0.83	-0.84	-0.62	-0.77	-0.51	-0.75	0.78		1.0	-0.92	-0.48	-0.46	-0.53	-0.8	0.85	-0.86	-0.85	0.66	-0.61	0.61	-0.17	0.69
Common Stock	-0.68	0.56	-0.92	0.62	-0.83	-0.84	-0.62	-0.77	-0.51	-0.75	0.78	1.0		-0.92	-0.48	-0.46	-0.53	-0.8	0.85	-0.86	-0.85	0.66	-0.61	0.61	-0.17	0.69
Long Term Debt	0.85	-0.39	0.94	-0.42	0.92	0.96	0.82	0.83	0.56	0.87	-0.66	-0.92	-0.92		0.63	0.7	0.68	0.8	-0.84	0.91	0.93	-0.47	0.68	-0.49	0.25	-0.62
Treasury Stock	0.59	-0.1	0.54	-0.03	0.51	0.62	0.53	0.52	0.26	0.54	-0.24	-0.48	-0.48	0.63		0.55	0.64	0.41	-0.53	0.56	0.58	-0.19	0.36	-0.14	0.03	-0.22
Property Plant Equipment	0.87	0.26	0.65	0.21	0.79	0.79	0.84	0.64	0.51	0.81	-0.16	-0.46	-0.46	0.7	0.55		0.68	0.65	-0.38	0.63	0.78	0.02	0.54	-0.34	0.5	-0.44
Good Will	0.61	-0.1	0.67	-0.08	0.59	0.66	0.53	0.79	0.37	0.64	-0.2	-0.53	-0.53	0.68	0.64	0.68		0.62	-0.62	0.7	0.69	-0.11	0.48	-0.45	0.28	-0.5
Current Deferred Revenue	0.8	-0.12	0.93	-0.22	0.9	0.82	0.72	0.79	0.75	0.91	-0.4	-0.8	-0.8	0.8	0.41	0.65	0.62		-0.49	0.63	0.71	-0.22	0.79	-0.71	0.59	-0.92
Net Tangible Assets	-0.49	0.72	-0.73	0.71	-0.59	-0.71	-0.45	-0.71	-0.19	-0.5	0.75	0.85	0.85	-0.84	-0.53	-0.38	-0.62	-0.49		-0.92	-0.81	0.66	-0.36	0.46	0.15	0.39
Long Term Debt Total	0.63	-0.54	0.8	-0.57	0.74	0.8	0.61	0.75	0.31	0.64	-0.73	-0.86	-0.86	0.91	0.56	0.63	0.7	0.63	-0.92		0.95	-0.59	0.46	-0.5	0.16	-0.46
Capital Surpluse	0.78	-0.35	0.86	-0.41	0.85	0.89	0.76	0.72	0.5	0.78	-0.67	-0.85	-0.85	0.93	0.58	0.78	0.69	0.71	-0.81	0.95		-0.55	0.61	-0.5	0.32	-0.55
Long Term Investments	-0.07	0.74	-0.41	0.8	-0.27	-0.29	-0.07	-0.17	-0.06	-0.14	0.88	0.66	0.66	-0.47	-0.19	0.02	-0.11	-0.22	0.66	-0.59	-0.55		-0.17	0.3	0.1	0.21
Short Long Term Debt	0.74	-0.12	0.8	-0.17	0.8	0.76	0.78	0.45	0.95	0.81	-0.26	-0.61	-0.61	0.68	0.36	0.54	0.48	0.79	-0.36	0.46	0.61	-0.17		-0.3	0.62	-0.75
Cash And Equivalents	-0.34	0.27	-0.66	0.38	-0.51	-0.43	-0.18	-0.71	-0.28	-0.52	0.42	0.61	0.61	-0.49	-0.14	-0.34	-0.45	-0.71	0.46	-0.5	-0.5	0.3	-0.3		-0.31	0.82
Net Invested Capital	0.42	0.3	0.41	0.16	0.51	0.33	0.44	0.19	0.65	0.53	-0.03	-0.17	-0.17	0.25	0.03	0.5	0.28	0.59	0.15	0.16	0.32	0.1	0.62	-0.31		-0.56
Net Working Capital	-0.59	0.18	-0.84	0.29	-0.74	-0.64	-0.5	-0.68	-0.73	-0.77	0.35	0.69	0.69	-0.62	-0.22	-0.44	-0.5	-0.92	0.39	-0.46	-0.55	0.21	-0.75	0.82	-0.56

Click cells to compare fundamentals

About Eli Lilly Financial Statements

Eli Lilly investors use historical fundamental indicators, such as Eli Lilly's Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Eli Lilly. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Stock Based Compensation	628.5 M	334.2 M
Stock Based Compensation To Revenue	0.02	0.01

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Eli Stock Analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eli Stock Based Compensation from 2010 to 2024

Latest Eli Lilly's Stock Based Compensation Growth Pattern

Eli Stock Based Compensation Regression Statistics

Eli Stock Based Compensation History

Other Fundumenentals of Eli Lilly

Eli Lilly Stock Based Compensation component correlations

About Eli Lilly Financial Statements

Also Currently Popular

Additional Tools for Eli Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY